Pear Therapeutics, Inc. (NASDAQ:PEAR) Major Shareholder 5Am Partners Iv, Llc Sells 285,067 Shares

Pear Therapeutics, Inc. (NASDAQ:PEARGet Rating) major shareholder 5Am Partners Iv, Llc sold 285,067 shares of the business’s stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $1.94, for a total value of $553,029.98. Following the transaction, the insider now directly owns 552,159 shares of the company’s stock, valued at approximately $1,071,188.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

5Am Partners Iv, Llc also recently made the following trade(s):

  • On Friday, September 16th, 5Am Partners Iv, Llc sold 351 shares of Pear Therapeutics stock. The stock was sold at an average price of $1.75, for a total value of $614.25.
  • On Thursday, September 8th, 5Am Partners Iv, Llc sold 304,322 shares of Pear Therapeutics stock. The stock was sold at an average price of $1.81, for a total value of $550,822.82.
  • On Tuesday, September 6th, 5Am Partners Iv, Llc sold 311,160 shares of Pear Therapeutics stock. The stock was sold at an average price of $2.36, for a total value of $734,337.60.
  • On Thursday, August 18th, 5Am Partners Iv, Llc sold 222,761 shares of Pear Therapeutics stock. The shares were sold at an average price of $1.55, for a total value of $345,279.55.
  • On Tuesday, August 16th, 5Am Partners Iv, Llc sold 167,162 shares of Pear Therapeutics stock. The shares were sold at an average price of $1.78, for a total value of $297,548.36.

Pear Therapeutics Price Performance

NASDAQ:PEAR opened at $1.69 on Friday. Pear Therapeutics, Inc. has a fifty-two week low of $1.34 and a fifty-two week high of $14.60. The company has a 50 day simple moving average of $1.71 and a two-hundred day simple moving average of $3.12.

Pear Therapeutics (NASDAQ:PEARGet Rating) last posted its quarterly earnings results on Thursday, August 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. The business had revenue of $3.30 million for the quarter, compared to the consensus estimate of $4.00 million. As a group, equities research analysts anticipate that Pear Therapeutics, Inc. will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On Pear Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of PEAR. SB Global Advisers Ltd bought a new position in shares of Pear Therapeutics during the 4th quarter worth approximately $75,020,000. Sarissa Capital Management LP bought a new position in shares of Pear Therapeutics in the 4th quarter worth $3,102,000. EDBI Pte Ltd bought a new position in shares of Pear Therapeutics in the 4th quarter worth $2,644,000. Sciencast Management LP bought a new position in shares of Pear Therapeutics in the 1st quarter worth $190,000. Finally, GSA Capital Partners LLP bought a new position in shares of Pear Therapeutics in the 1st quarter worth $146,000. 55.39% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on PEAR. BTIG Research lowered their price objective on Pear Therapeutics from $11.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, August 12th. Lifesci Capital reaffirmed an “outperform” rating on shares of Pear Therapeutics in a research note on Thursday, June 16th. Chardan Capital lowered their price objective on Pear Therapeutics from $13.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, August 12th. Finally, Credit Suisse Group decreased their target price on shares of Pear Therapeutics from $11.00 to $9.00 and set an “outperform” rating for the company in a research report on Tuesday, July 26th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

About Pear Therapeutics

(Get Rating)

Pear Therapeutics, Inc, a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia.

Featured Stories

Receive News & Ratings for Pear Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pear Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.